Pfizer bags rull FDA nod for BRAFTOVI combination in aggressive colorectal cancer
BRAFTOVI in combination with cetuximab and mFOLFOX6 had previously received accelerated approval in December 2024 based on objective response rate (ORR) results
BRAFTOVI in combination with cetuximab and mFOLFOX6 had previously received accelerated approval in December 2024 based on objective response rate (ORR) results
The approved product is a generic version of the reference listed drug (RLD) Lamictal ODT by GlaxoSmithKline and is indicated for the treatment of epilepsy and bipolar disorder
Sugemalimab, developed using CStone’s OmniRat transgenic platform, is a fully human IgG4 monoclonal antibody designed to minimize immunogenicity and toxicity
The innovative eyedrop targets inflammation and pain following ocular surgery
CagriSema produced a 23% weight loss at 84 weeks, versus 25.5% for tirzepatide
NCFB is a chronic lung condition where damaged airways cause persistent coughing and mucus production
To support this launch, ImmunityBio has established a wholly owned subsidiary in Saudi Arabia
Prostate cancer is one of the fastest-growing cancers in India, with approximately 37,948 new cases each year
Subscribe To Our Newsletter & Stay Updated